Effects of silymarin on neuropathic pain and formalin-induced nociception in mice


1 School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

2 Department of Physiology and Pharmacology, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran

3 Department of Pharmacology and Toxicology, School of Pharmacy, Zabol University of Medical Sciences, Zabol, Iran

4 Medical Toxicology Research Center and Pharmacy School, Mashhad University of Medical Sciences, Mashhad, Iran


Objective(s):Based on the previous reports, silymarin can suppress nitric oxide, prostaglandin E2 (PGE2), leukotrienes, cytokines production, and neutrophils infiltration. Regarding the fact that inflammation plays an important role in neuropathic and formalin-induced pain, it was assumed that silymarin could reduce pain. The present study investigates the analgesic effects of silymarin in chemical nociception and a model of neuropathic pain.
Materials and Methods: Chemical nociception was produced by injection of 20 µl of formalin (0.5% formaldehyde in saline) into the plantar region of the right hind paw. A sciatic-nerve ligated mouse was applied as the model of neuropathic pain and the antinociceptive response of silymarin was examined 14 days after unilateral nerve-ligation using the hot plate test.
Results:The intraperitoneal administration of silymarin (25, 50, and, 100 mg/kg) 2 hr prior to the intraplantar formalin injection suppressed the nociceptive response during the late phase of the formalin test significantly, but it was not in a dose-dependent manner. Different doses of silymarin 14 days after unilateral sciatic nerve ligation in hot plate test did not induce obvious antinociception.
Conclusion:Results of the present study indicated that repeated administration of silymarin prevents the formalin-induced nociceptive behavior. However, it is not effective in the treatment of sciatic neuropathic pain.


1.   Dray A. Inflammatory mediators of pain. Br J Anaesth1995; 75:125-131.

2.   Rittner H, Machelska H, Stein C. Leukocytes in the regulation of pain and analgesia. J Leukocyte Biol2005; 78:1215-1222.

3.   Sommer C, Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett2004; 361:184-187.

4.   Iranshahi M, Askari M, Sahebkar A, Adjipavlou-Litina D. Evaluation of antioxidant, anti-inflammatory and lipoxygenase inhibitory activities of the prenylated coumarin umbelliprenin. DARU2009; 17:99-103.

5.   Monsef HR, Ghobadi A, Iranshahi M, Abdollahi M. Antinociceptive effects of Peganum harmala L. alkaloid extract on mouse formalin test. J Pharm Pharm Sci2004; 7:65-69.

6.   Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs2001; 15:465-489.

7.   Karimi G, Vahabzadeh M, Lari P, Rashedinia M, Moshiri M. "Silymarin", a promising pharmacological agent for treatment of diseases. Iran J Basic Med Sci2011, 14:308-317.

8.   Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989; 9:105-113.

9.   Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs2001; 61:2035-2063.

10. Gupta OP, Sing S, Bani S, Sharma N, Malhotra S, Gupta BD, et al. Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. Phytomedicine2000; 7:21-24.

11. Kang JS, Jeon YJ, Park S-K, Yang K-H, Kim HM. Protection against lipopolysaccharide-induced sepsis and inhibition of interleukin-1β and prostaglandin E2 synthesis by silymarin. Biochem Pharmacol 2004; 67:175-181.

12. Manna SK, Mukhopadhyay A, Van NT, Aggarwal BB. Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis. J Immunol1999; 163:6800-6809.

13. Nazemian F, Karimi G, Moatamedi M, Charkazi S, Shamsara J, Mohammadpour AH. Effect of silymarin administration on TNF-alpha serum concentration in peritoneal dialysis patients. Phytother Res2010; 24:1654-1657.

14. Taghiabadi E, Imenshahidi M, Abnous Kh, Mosafa F, Sankian M, Memar M, et al. Protective Effect of Silymarin against Acrolein-Induced Cardiotoxicity in Mice. Evid Based Complement Alternat Med 2012; 2012:352091.

15. Dubuisson D, Dennis SG. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 1977; 4:161-174.

16. Hunskaar S, Hole K. The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. Pain1987; 30:103-114.

17. Mota VG, de Carvalho FL, de Morais LCSL, Bhattacharyya J, de Almeida RN, de Alencar JL. Antinociceptive activity of the chloroform fraction of Dioclea virgata (Rich.) Amshoff (Fabaceae) in mice. Biomed Res Int2011; 2011: 342816.

18. Seltzer Ze, Dubner R, Shir Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain1990; 43:205-218.

19. Karimi G, Tabrizian K, Rezaee R. Evaluation of the analgesic effect of dextromethorphan and its interaction with nitric oxide on sciatic nerve ligated rats. J Acupunct Meridian Stud2010; 3:38-42.

20. Eddy NB, Leimbach D. Synthetic analgesics. II. Dithienylbutenyl- and dithienylbutylamines. J Pharmacol Exp Ther 1953; 107:385-393.

21. Puerta R, Martinez E, Bravo L, Ahumada M. Effect of silymarin on different acute inflammation models and on leukocyte migration. J Pharm Pharmacol1996; 48:968-970.

22. Shibata M, Ohkubo T, Takahashi H, Inoki R. Modified formalin test: characteristic biphasic pain response. Pain1989; 38:347-352.

23. Ferreira AA, Amaral FA, Duarte IDG, Oliveira PM, Alves RB, Silveira D, et al. Antinociceptive effect from Ipomoea cairica extract. J Ethnopharmacol2006; 105:148-153.

24. Woolf CJ, Mannion RJ. Neuropathic pain:
aetiology, symptoms, mechanisms, and management. Lancet1999, 353:1959-1964.

25. Kingery WS. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. Pain1997; 73:123-139.

26. Olsson Y. Degranulation of mast cells in peripheral nerve injuries. Acta Neurol Scand1967; 43:365-374.

27. Perry V, Brown M, Gordon S. The macrophage response to central and peripheral nerve injury. A possible role for macrophages in regeneration. J Exp Med1987; 165:1218-1223.

28. Moalem G, Tracey DJ. Immune and inflammatory mechanisms in neuropathic pain. Brain Res Rev2006; 51:240-264.

29. Yalcin I, Choucair-Jaafar N, Benbouzid M, Tessier LH, Muller A, Hein L, et al. beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol2009; 65:218-225.

30. Bohren Y, Tessier LH, Megat S, Petitjean H, Hugel S, Daniel D, et al. Antidepressants suppress neuropathic pain by a peripheral beta2-adrenoceptor mediated anti-TNFalpha mechanism. Neurobiol Dis2013; 60:39-50.

31. Vissers KC, Geenen F, Biermans R, Meert TF. Pharmacological correlation between the formalin test and the neuropathic pain behavior in different species with chronic constriction injury. Pharmacol Biochem Behav 2006; 84:479-486.

32. Munro G. Pharmacological assessment of the rat formalin test utilizing the clinically used analgesic drugs gabapentin, lamotrigine, morphine, duloxetine, tramadol and ibuprofen: influence of low and high formalin concentrations. Eur J Pharmacol 2009; 605:95-102.